WiseGuyRerports Introduced “Global Cardiovascular Drug Market Research Report 2019” New Document to its Studies Database
Cardiovascular disease is a major cause of death across the world. These diseases primarily include heart issues, blood vessel disorders, stroke, atherosclerosis, coronary, and peripheral artery diseases among others. Cardiovascular drugs include anti-hypertensive drugs for controlling blood pressure, hypolipidemic drugs for reducing lipoprotein levels in the blood, or antithrombotic drugs used to treat arterial and venous thrombosis.
This report analyses the current status of the global cardiovascular drug market, outlines the key market drivers and the bases for market segmentation, and studies the future trends of this industry from 2019 till 2025, using 2018 as the historical base.
The global cardiovascular drug market is expected to reach a value of almost USD 86.67 billion by 2022, growing at a CAGR of 1.2% till 2022. The growth drivers for this market include an increase in the geriatric population, rise in the prevalence of cardiovascular diseases, and the availability of newer varieties of generic drugs that reduce the cost of treatment.
The major manufacturers
Bristol Myers Squibb and Pfizer
Johnson & Johnson
Merck & Co.
Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/3772612-global-cardiovascular-drug-market-research-report-2019
The global cardiovascular drug market can be segmented according to type of drug, application, and geographical region.
By type of drug, this market can be split into:
- Anti-hypertensive drugs
- Other drugs for cardiovascular diseases
Among these segments, it has been seen that the anti-hypertensive drugs segment occupies the major chunk of the market share. The hypertension segment recorded USD 64.9 billion in terms of revenue in 2009, and is expected to be the largest segment during the forecast period.
According to application, the market can be split into hospitals, clinics, and others.
North America, Europe, Asia-Pacific, and the Rest of the World are the major regions for the cardiovascular drug market across the world. North America accounts for the largest market share of more than 60%, followed by Europe, Asia Pacific, and the Rest of the World. In North America, the US is one of the major contributors to the growth of this market.
In Europe, Germany, U.K., Spain, Italy, and France hold the major share of the cardiovascular drugs market. However, the Asia-Pacific region, especially in India, China and Japan, is expected to show substantial growth in this market during the forecast period. This could be due to the fact that several pharma companies are building their research and development facilities in this region, as well as the easier availability of skilled and cheap labor. Additionally, an increasing awareness about heart related ailments is also boosting growth.
According to the latest trends in the global cardiovascular drug market, Non-Vitamin K antagonist oral anticoagulants (NOAC) are gaining in popularity and are being used in place of traditional anti-coagulants such as Warfarin and Heparin which are used to treat cardiovascular disease. The use of NOACs makes it easier for patients to continue treatment post discharge from hospital while injections of Heparin and Warfarin need medical assistance to be administered.
In January 2017, J&J acquired Actelion, and added the pulmonary arterial hypertension drugs Uptravi and Opsumit to its portfolio, which are expected to secure the company’s position as a market leader in this segment and provide stiff competition to Warfarin.
Complete Report Details @ https://www.wiseguyreports.com/reports/3772612-global-cardiovascular-drug-market-research-report-2019
Table Of Content:
1 Study Coverage
2 Executive Summary
3 Breakdown Data by Manufacturers
4 Breakdown Data by Product
5 Breakdown Data by End User
6 North America
8 Asia Pacific
9 Central & South America
10 Middle East and Africa
11 Company Profiles
12 Future Forecast
13 Value Chain and Sales Channels Analysis
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)